Lars Thompson, MD
Urology · Canton, NYNPI 1063511772
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.8% of the total across 202 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations.
Across 202 payments — averaging $22.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$781
- Pfizer$689
- Astellas Pharma US Inc$505
- AbbVie$481
- Johnson & Johnson$303
- Dendreon Pharmaceuticals LLC$278
- plus $2K from 21 others
What the payments were for
- Travel & lodging$1463%
- Food & beverage$4,13191%
- Education$2756%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 32 | $781 |
| Pfizer | 39 | $689 |
| Astellas Pharma US Inc | 22 | $505 |
| AbbVie | 22 | $481 |
| Johnson & Johnson | 12 | $303 |
| Dendreon Pharmaceuticals LLC | 16 | $278 |
| Neotract Inc. | 6 | $251 |
| Teleflex LLC | 8 | $203 |
| Accord Healthcare, Inc. | 2 | $128 |
| Novartis | 1 | $120 |
| Sumitomo Pharma America, Inc. | 6 | $106 |
| Endo USA, Inc. | 5 | $96 |
| Ferring Pharmaceuticals Inc. | 4 | $91 |
| Telix Pharmaceuticals | 5 | $80 |
| 180 Medical, Inc. | 4 | $73 |
| Urovant Sciences Inc | 3 | $60 |
| Merck | 2 | $54 |
| Myovant Sciences Inc. | 3 | $46 |
| E.r. Squibb & Sons, L.L.C. | 1 | $37 |
| Olympus America Inc. | 2 | $36 |
| Tolmar Pharmaceuticals, Inc. | 1 | $21 |
| Endo Pharmaceuticals Inc. | 1 | $21 |
| Boston Scientific | 1 | $20 |
| Medtronic | 1 | $20 |
| Smith+Nephew | 1 | $19 |
| Coloplast | 1 | $15 |
| AstraZeneca | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,552 in reported general payments places this provider in the 60th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 72 | $1,262,893 |
| OrgovyxRelugolix | 74 | $195,899 |
| GemtesaVibegron | 58 | $59,616 |
| MyrbetriqMirabegron | 53 | $59,042 |
| Estradiol | 246 | $29,406 |
| Testosterone | 66 | $24,131 |
| Mirabegron ErMirabegron | 26 | $22,914 |
| Tamsulosin Hcl | 873 | $20,111 |
| Fosfomycin Tromethamine | 39 | $14,812 |
| Finasteride | 817 | $12,332 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 326 | $6,531 |
| Potassium Citrate ErPotassium Citrate | 61 | $6,508 |
| Testosterone Cypionate | 71 | $4,999 |
| Tadalafil | 15 | $4,205 |
| Tolterodine Tartrate | 12 | $3,617 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $505 | $1,321,935125 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $106 | $255,514132 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 952 urology providers in New York.
Other urology in Canton
- Peter WalterJamestown$1.9M
- Christopher PieczonkaSyracuse$797K
- Bilal ChughtaiNew York$658K
- Katie MurrayNew York$575K
- Neil BanderNew York$544K
- Robert ValenzuelaNew York$494K
- Jeffrey SpencerCheektowaga$430K
- Kyrollis AttallaNew York$381K
- Benjamin BruckerNew York$364K
- Evan GoldfischerPoughkeepsie$314K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.